172 related articles for article (PubMed ID: 33380937)
1. Amlexanox: A Novel Therapeutic for Atopic, Metabolic, and Inflammatory Disease.
Dosanjh A; Won CY
Yale J Biol Med; 2020 Dec; 93(5):759-763. PubMed ID: 33380937
[TBL] [Abstract][Full Text] [Related]
2. Amlexanox attenuates LPS-induced neuroinflammatory responses in microglial cells via inhibition of NF-κB and STAT3 signaling pathways.
Phan Van T; Huyen Ton Nu Bao T; Leya M; Zhou Z; Jeong H; Lim CW; Kim B
Sci Rep; 2024 Feb; 14(1):2744. PubMed ID: 38302598
[TBL] [Abstract][Full Text] [Related]
3. Amlexanox reversed non-alcoholic fatty liver disease through IKKε inhibition of hepatic stellate cell.
He Q; Xia X; Yao K; Zeng J; Wang W; Wu Q; Tang R; Zou X
Life Sci; 2019 Dec; 239():117010. PubMed ID: 31672578
[TBL] [Abstract][Full Text] [Related]
4. Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro.
Zhou Z; Qi J; Lim CW; Kim JW; Kim B
Toxicology; 2020 Nov; 444():152579. PubMed ID: 32905826
[TBL] [Abstract][Full Text] [Related]
5. Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKK
Beyett TS; Gan X; Reilly SM; Chang L; Gomez AV; Saltiel AR; Showalter HD; Tesmer JJG
Mol Pharmacol; 2018 Oct; 94(4):1210-1219. PubMed ID: 30082428
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of TBK1 by amlexanox attenuates paraquat-induced acute lung injury.
Wang N; Li Y; Wang X; Ma Z; Wang Y; Zhang C; Yuan Y; Zhao M
Toxicology; 2020 Oct; 443():152555. PubMed ID: 32763286
[TBL] [Abstract][Full Text] [Related]
7. Amlexanox exerts anti-inflammatory actions by targeting phosphodiesterase 4B in lipopolysaccharide-activated macrophages.
Han Y; Hou R; Zhang X; Liu H; Gao Y; Li X; Qi R; Cai R; Qi Y
Biochim Biophys Acta Mol Cell Res; 2020 Oct; 1867(10):118766. PubMed ID: 32504661
[TBL] [Abstract][Full Text] [Related]
8. Amlexanox ameliorates acetaminophen-induced acute liver injury by reducing oxidative stress in mice.
Qi J; Zhou Z; Lim CW; Kim JW; Kim B
Toxicol Appl Pharmacol; 2019 Dec; 385():114767. PubMed ID: 31697998
[TBL] [Abstract][Full Text] [Related]
9. Amlexanox Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss.
Zhang Y; Guan H; Li J; Fang Z; Chen W; Li F
Sci Rep; 2015 Sep; 5():13575. PubMed ID: 26338477
[TBL] [Abstract][Full Text] [Related]
10. The TBK1/IKKε inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis.
Zhao P; Sun X; Liao Z; Yu H; Li D; Shen Z; Glass CK; Witztum JL; Saltiel AR
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35917178
[TBL] [Abstract][Full Text] [Related]
11. Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction.
Cruz VH; Arner EN; Wynne KW; Scherer PE; Brekken RA
Mol Metab; 2018 Oct; 16():139-149. PubMed ID: 29935921
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes.
Oral EA; Reilly SM; Gomez AV; Meral R; Butz L; Ajluni N; Chenevert TL; Korytnaya E; Neidert AH; Hench R; Rus D; Horowitz JF; Poirier B; Zhao P; Lehmann K; Jain M; Yu R; Liddle C; Ahmadian M; Downes M; Evans RM; Saltiel AR
Cell Metab; 2017 Jul; 26(1):157-170.e7. PubMed ID: 28683283
[TBL] [Abstract][Full Text] [Related]
13. Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.
Cheng C; Ji Z; Sheng Y; Wang J; Sun Y; Zhao H; Li X; Wang X; He Y; Yao J; Wang L; Zhang C; Guo Y; Zhang J; Gao WQ; Zhu HH
Theranostics; 2018; 8(17):4633-4648. PubMed ID: 30279728
[TBL] [Abstract][Full Text] [Related]
14. Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor.
Ozasa K; Temizoz B; Kusakabe T; Kobari S; Momota M; Coban C; Ito S; Kobiyama K; Kuroda E; Ishii KJ
Front Immunol; 2019; 10():2212. PubMed ID: 31616416
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor.
Homan KT; Wu E; Cannavo A; Koch WJ; Tesmer JJ
Molecules; 2014 Oct; 19(10):16937-49. PubMed ID: 25340299
[TBL] [Abstract][Full Text] [Related]
16. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.
He Q; Zeng J; Yao K; Wang W; Wu Q; Tang R; Xia X; Zou X
Biochem Biophys Res Commun; 2020 Nov; 532(3):362-369. PubMed ID: 32883523
[TBL] [Abstract][Full Text] [Related]
17. [Inhibitory effect of amlexanox on asthmatic attacks in an aspirin sensitive asthmatic].
Inagaki M; Michimata H; Minato K; Sunaga Y; Kobayashi S; Tani G; Nakazawa T
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Jun; 30(6):1180-5. PubMed ID: 1507696
[TBL] [Abstract][Full Text] [Related]
18. Amlexanox Blocks the Interaction between S100A4 and Epidermal Growth Factor and Inhibits Cell Proliferation.
Cho CC; Chou RH; Yu C
PLoS One; 2016; 11(8):e0161663. PubMed ID: 27559743
[TBL] [Abstract][Full Text] [Related]
19. FGF21 is required for the metabolic benefits of IKKε/TBK1 inhibition.
Reilly SM; Abu-Odeh M; Ameka M; DeLuca JH; Naber MC; Dadpey B; Ebadat N; Gomez AV; Peng X; Poirier B; Walk E; Potthoff MJ; Saltiel AR
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822771
[TBL] [Abstract][Full Text] [Related]
20. An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.
Reilly SM; Chiang SH; Decker SJ; Chang L; Uhm M; Larsen MJ; Rubin JR; Mowers J; White NM; Hochberg I; Downes M; Yu RT; Liddle C; Evans RM; Oh D; Li P; Olefsky JM; Saltiel AR
Nat Med; 2013 Mar; 19(3):313-21. PubMed ID: 23396211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
